Two Securities Class Action Lawsuits Filed Against Biopharmaceutical Companies Over Alleged Clinical Trial Misstatements
Two securities class action lawsuits have been filed against NASDAQ-listed biopharmaceutical companies Ultragenyx and Vistagen. Both cases allege defendants made misleading statements about clinical trial results for key drug programs. Investors face deadlines in March and April 2026 to request lead plaintiff status.
Two separate securities class action lawsuits have been filed against NASDAQ-listed biopharmaceutical companies, with both cases alleging that defendants made false and misleading statements to investors about the prospects of key drug development programs.
The first lawsuit targets Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) and certain of its officers. The complaint seeks to recover damages on behalf of all persons and entities that purchased or otherwise acquired Ultragenyx securities between August 3, 2023 and December 26, 2025. Investors who wish to join the case must request that the Court appoint them as lead plaintiff by April 6, 2026. The lawsuit alleges that defendants created the false impression that they possessed reliable information pertaining to the effects of setrusumab on patients with variable types of Osteogenesis Imperfecta ("OI"), while minimizing the risk that patients in the Phase III Orbit study would fail to achieve a statistically significant reduction in annualized fracture rate. The complaint further alleges that Ultragenyx's optimism in the Phase III Orbit study's results and interim analysis benchmark were misplaced because the company failed to convey the risk associated with basing such threshold figures on Phase II results that had no placebo control group for appropriate comparison and had not ruled out that the reduction in annualized fracture rate could merely be triggered by an increased standard of care and the placebo effect of being provided a novel treatment.
The second lawsuit targets Vistagen Therapeutics, Inc. (NASDAQ: VTGN). The class action covers purchasers of common stock between April 1, 2024 and December 16, 2025, with a lead plaintiff deadline of March 16, 2026. The lawsuit alleges that defendants provided investors with material information concerning Vistagen's plan to develop and commercialize fasedienol, an investigational pherine candidate in development for the acute treatment of social anxiety disorder. Defendants' statements included positive assertions of fasedienol's future trial success based on prior positive results associated with the PALISADE-2 clinical trial, and assertions that enhancements and operational changes made to the execution of the PALISADE-3 clinical trial supported a strong likelihood of Phase 3 success. According to the lawsuit, defendants disseminated false and misleading statements while simultaneously concealing material adverse facts concerning the Phase 3 PALISADE-3 trial study of fasedienol.